Results 41 to 50 of about 31,905 (272)

Predictors of Diffusing Capacity in Children With Sickle Cell Disease: A Longitudinal Study

Frontiers in Pediatrics, 2021
Background: Gas exchange abnormalities in Sickle Cell Disease (SCD) may represent cardiopulmonary deterioration. Identifying predictors of these abnormalities in children with SCD (C-SCD) may help us understand disease progression and develop informed ...
Pritish Mondal, Vishal Midya, Arshjot Khokhar, Shyama Sathianathan, Erick Forno   +4 more
doaj   +1 more source

Time-based understanding of DLCO and DLNO

Respiratory Physiology & Neurobiology, 2016
Capture of CO and NO by blood requires molecules to travel by diffusion from alveolar gas to haemoglobin molecules inside RBCs and then to react. One can attach to these processes two times, a time for diffusion and a time for reaction. This reaction time is known from chemical kinetics and, therefore, constitutes a unique physical clock.
Bernard Sapoval, Min-Yeong Kang
openaire   +3 more sources

Characteristics of the elderly in high - resolution computed tomography lung densitometry [PDF]

, 2004
To determine the characteristics of the elderly in high - resolution computed tomography (HRCT) lung densitometry, mean lung density (MLD) and relative area of the lungs showing attenuation values less than -950 HU (RA(950)) on HRCT were evaluated in ...
Ashida, Kozo, Fujii, Makoto, Hamada, Masanori, Hosaki, Yasuhiro, Iwagaki, Naofumi, Mitsunobu, Fumihiro, Nagata, Takuya, Takata, Shingo, Tanizaki, Yoshiro, Yokoi, Tadashi   +9 more
core   +1 more source

Amiodarone-Induced Pulmonary Toxicity - A Frequently Missed Complication. [PDF]

, 2016
IntroductionAmiodarone is often used in the suppression of tachyarrhythmias. One of the more serious adverse effects includes amiodarone pulmonary toxicity (APT).
Dang, Natasha, Datta, Jyoti, Lam, Vinh, Singh, Navneet K, Sweidan, Alexander J   +4 more
core   +2 more sources

Endobronchial Valve Treatment in Emphysema Patients with a Very Low DLCO [PDF]

Respiration, 2020
<b><i>Background:</i></b> For selected patients with severe emphysema, bronchoscopic lung volume reduction with endobronchial valves (EBV) is recognized as an additional treatment option. In most trials investigating EBV treatment, patients with a very low diffusing capacity (DLCO) were excluded from participation.
Marlies van Dijk, Jorine E. Hartman, Karin Klooster, Nick H.T. Ten Hacken, Huib A.M. Kerstjens, Dirk-Jan Slebos   +5 more
openaire   +3 more sources

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference [PDF]

, 2010
The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in walk distance that constitutes the minimum important difference (MID) over time is ...
Behr, Jürgen, Brown, Kevin K., du Bois, Roland M., King, Talmadge E., Raghu, Ganesh, Swigris, Jeffrey J., Wamboldt, Frederick S.   +6 more
core   +1 more source

Prediction equations for diffusing capacity (transfer factor) of lung for North Indians

Lung India, 2016
Background: Prediction equations for diffusing capacity of lung for carbon monoxide (DLCO), alveolar volume (VA), and DLCO/VA using the current standardization guidelines are not available for Indian population.
Sunil Kumar Chhabra, Rajeev Kumar, Uday A Gupta   +2 more
doaj   +1 more source

P267 Dlco predicts disease severity and mortality in bronchiectasis [PDF]

Thorax, 2016
Background Few studies have assessed the role of lung diffusing capacity (DLCO%) in bronchiectasis. We sought to examine the relationship between DLCO% and clinical and radiological variables in a well-defined population of bronchiectasis patients to determine its potential prognostic significance and compare with FEV1%.
Robert Rutherford, David P. Breen, Anthony O'Regan, Melissa J. McDonnell, J. J. Gilmartin, Michael O'Mahony   +5 more
openaire   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]

, 2017
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco, Carns, Mary, Chung, Lorinda, Criswell, Lindsey A, Derk, Chris T, Domsic, Robyn T, Gladue, Heather, Goldberg, Avram, Gordon, Jessica K, Gourh, Pravitt, Hsu, Vivien, Jan, Reem, Kastner, Daniel L, Khanna, Dinesh, Mayes, Maureen D, Medsger, Thomas A, Morgan, Nadia D, Ramos, Paula S, Remmers, Elaine F, Saketkoo, Lesley A, Schiopu, Elena, Shah, Ami A, Shanmugam, Victoria K, Silver, Richard M, Steen, Virginia D, Trojanowski, Marcin A, Valenzuela, Antonia, Varga, John, Wigley, Fredrick M   +28 more
core   +1 more source